417 related articles for article (PubMed ID: 8402669)
1. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
[TBL] [Abstract][Full Text] [Related]
2. N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
Grem JL; Yee LK; Schuler B; Hamilton JM; Chen AP; Chabuk C; Grollman F; Grabenc M; Allegra CJ; Takimoto CH
Ann Oncol; 2001 Nov; 12(11):1581-7. PubMed ID: 11822758
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent inhibition of aspartate carbamoyltransferase in peripheral blood mononuclear cells in patients receiving N-(phosphonacetyl)-L-aspartate.
Grem JL; McAtee N; Drake JC; Steinberg S; Allegra CJ
Adv Exp Med Biol; 1993; 339():119-23. PubMed ID: 8178710
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Hageboutros A; Rogatko A; Newman EM; McAleer C; Brennan J; LaCreta FP; Hudes GR; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1995; 35(3):205-12. PubMed ID: 7805178
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Murphy RF; Hamilton JM; Balis F; Steinberg S; Arbuck SG; Setser A; Jordan E; Chen A
J Clin Oncol; 1994 Mar; 12(3):560-8. PubMed ID: 8120554
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
Ardalan B; Ucar A; Reddy R; Livingstone AS; Markoe A; Schwade J; Richman SP; Donofrio K
Cancer; 1994 Oct; 74(7):1869-73. PubMed ID: 8082092
[TBL] [Abstract][Full Text] [Related]
8. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Ardalan B; Sridhar KS; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Fodor M; Livingstone A
Cancer; 1991 Sep; 68(6):1242-6. PubMed ID: 1873776
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of continuous-infusion PALA and 5-FU.
Ardalan B; Jamin D; Jayaram HN; Presant CA
Cancer Treat Rep; 1984 Mar; 68(3):531-4. PubMed ID: 6231102
[TBL] [Abstract][Full Text] [Related]
10. Effects of PALA on the pharmacokinetics of 5-fluorouracil.
Nassim MA; Rouini MR; Cripps MC; Shirazi FH; Veerasinghan S; Molepo JM; Obrocea M; Redmond D; Bates S; Fry D; Stewart DJ; Goel R
Oncol Rep; 1998; 5(1):217-21. PubMed ID: 9458325
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
Hageboutros A; Hudes GR; Brennan J; Green F; Hoffman J; LaCreta FP; Colofiore J; Martin DS; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1996; 37(3):229-34. PubMed ID: 8529282
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
Hageboutros A; Hudes GR; Greene F; LaCreta FP; Brennan J; O'Dwyer PJ
Invest New Drugs; 1997; 15(2):139-45. PubMed ID: 9220293
[TBL] [Abstract][Full Text] [Related]
13. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
Kemeny N; Conti JA; Seiter K; Niedzwiecki D; Botet J; Martin D; Costa P; Wiseberg J; McCulloch W
J Clin Oncol; 1992 May; 10(5):747-52. PubMed ID: 1569447
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
Weiss GR; Ervin TJ; Meshad MW; Schade D; Branfman AR; Bruni RJ; Chadwick M; Kufe DW
Cancer Chemother Pharmacol; 1982; 8(3):301-4. PubMed ID: 7127661
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Ardalan B; Stridhar K; Reddy R; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Livingstone A
Int J Radiat Oncol Biol Phys; 1992; 22(3):511-4. PubMed ID: 1735689
[TBL] [Abstract][Full Text] [Related]
16. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
Köhne CH; Harstrick A; Hiddemann W; Schöffski P; Wilke H; Bokemeyer C; Dörken B; Schmoll HJ
Eur J Cancer; 1997 Oct; 33(11):1896-9. PubMed ID: 9470854
[TBL] [Abstract][Full Text] [Related]
17. Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
Chiuten DF; Valdivieso M; Bedikian A; Bodey GP; Freireich EJ
Cancer Treat Rep; 1985 Jun; 69(6):611-3. PubMed ID: 4016768
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
Ardalan B; Singh G; Silberman H
J Clin Oncol; 1988 Jun; 6(6):1053-8. PubMed ID: 3373260
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of combination therapy with PALA and 5-FU.
Meshad MW; Ervin TJ; Kufe D; Johnson RK; Blum RH; Frei E
Cancer Treat Rep; 1981; 65(3-4):331-4. PubMed ID: 6263472
[TBL] [Abstract][Full Text] [Related]
20. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
Seiter K; Kemeny N; Martin D; Schneider A; Williams L; Colofiore J; Sawyer R
Cancer; 1993 Mar; 71(5):1875-81. PubMed ID: 8448752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
